Scott M. Schuetze

TL;DR: The primary endpoint of overall response was not met, but pembrolizumab showed encouraging activity in patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma, and expansion to expanded cohorts of those subtypes is ongoing.

TL;DR: The results show that integrative sequence analysis provides a clinically relevant, multi-dimensional view of the complex molecular landscape and microenvironment of metastatic cancers.

TL;DR: These studies establish NAB2-STAT6 as the defining driver mutation of SFT and provide an example of how neoplasia can be initiated by converting a transcriptional repressor of mitogenic pathways into an transcriptional activator.

TL;DR: Because disease control in advanced sarcomas is a clinically relevant end point, this study supports the activity of trabectedin for patients with these malignancies.

TL;DR: Denosumab was associated with tumour responses and reduced the need for morbid surgery in patients with GCTB and represents a new treatment option for patients with the rare giant cell tumour of bone.